Ultra fast-acting insulin analogue - Adocia

Drug Profile

Ultra fast-acting insulin analogue - Adocia

Alternative Names: BC 106 Insulin Lispro; BC 222 Insulin Lispro; BioChaperone Lispro; BioChaperone Lispro U100; BioChaperone Lispro U200; BioChaperone® insulin analogue; BioChaperone® insulin lispro; BioChaperone® Ultra Fast Lispro

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Recombinant proteins
  • Mechanism of Action Phosphokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 27 Jan 2017 Ultra fast-acting insulin analogue - Adocia is available for licensing as of 27 Jan 2017. http://www.adocia.fr/WP/
  • 27 Jan 2017 Eli Lilly terminated the agreement which was signed in December 2014 with Adocia for the joint development and commercialisation of BioChaperone® Lispro
  • 16 Dec 2016 Interim efficacy and adverse events data from a phase I trial in Type 1 diabetes mellitus released by Adocia and Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top